digit test and on the SSQ questionnaire. The authors report that these results lead to the rejection of the hypothesis. To me, these results confirm the hypothesis -indeed, the remote care did not harm.
-
The authors do a very good job at comparing two pathways: remote care and standard care. In the Discussion, when raising clinical implications, it could be interesting to nuance this duality between the two pathways and suggest that many patients will benefit from hybrid pathways (mix of remote and standard care), personalised according to their needs, preferences, etc. The authors hint to this in the Results section under Clinician preference for and experience of remote care and in the Conclusions, but the point could be made stronger.
-I enjoyed the Discussion regarding the limitations of the PAM questionnaire for this population. What alternative measures do the authors suggest? What do the authors think of the related Partners in Health scale (Smith et al, 2017) ? -Minor thing: Why was it important to randomise participants according to gender? There are few studies pointing to a gender effect in hearing care.
Minor thing: It is really neat that the authors make their dataset openly available. However, the DOI provided did not work for me.
REVIEWER
Azadeh Ebrahimi-Madiseh Ear Science Institute Australia (ESIA) / University of Western Australia (UWA) Australia REVIEW RETURNED 28-Oct-2017
GENERAL COMMENTS
This manuscript is a randomised controlled trial to evaluate the feasibility of a personalised remote care for long term follow-ups of adult cochlear implant recipients. The study is unique in remotely evaluating all aspects of a CI recipient's progress including monitoring the function via speech perception tests, fine-tuning and rehabilitation.
Rationale of the study is well argued and referenced. Despite a few minor changes required, abstract has well and clearly been written. Ethics approval has been received and ethical issues raised during the study were properly addressed. Conflict of interests and funding information has also been clearly reported.
Methodology is appropriate to answer the research question, however there are ambiguities in the manuscript that need to be addressed. Restructuring of the methodology section is highly recommended, as the contents do not flow. A suggestion would be to start with Trial design and setting, followed by randomisation and blinding, participants and recruitment, Intervention, Outcome measure, hypothesis, statistical analysis and data handling. There are minor explanations and clarifications required in the result and discussion section.
Introduction

5.
Page 6, line 6: " provide hearing to people with severe to profound deafness" to be changed to " provide hearing to people mainly with severe to profound deafness". With the expansion of criteria, CI is given to and improves hearing of people with less severe hearing losses in many countries. 6.
Page 6, line 11: Please explain the clinic-led follow-ups. Does the author suggest that the client is called to these appointments when unnecessary? 7.
Page 6, line 19-22: The majority of CI recipients lose the residual hearing following implantation specially severe to profound recipients. Please explain what you mean by "detection of deterioration in hearing". Perhaps speech recognition instead? 8.
Page 6, line 36: "better hearing as they provide an ability to fine tune when away from clinic ". Better hearing is a very general and inaccurate term; better in what way? It is suggested to be changed to " more realistic adjustments of the CI device in real life situations as recipients are provided an ability……..)
Methods
9.
Page 8, line 9: "The protocol was published previously." To be changed to: "The protocol was previously published." 10.
Page 8, line 19: If any participant in the control group had any extra visits to the clinic (faulty device, request fine tuning,…), please explain how this was controlled and report it in the result section, please. 11.
Page 9, lines 19-22: Please briefly explain what involves in a normal care pathway. 12.
Page 8, line 43: "Remote and self monitoring"; The title is vague. A suggestion would be " Remote and self monitoring of speech understanding or performance" 13.
Page 8, Line 51: "Participants listened to sets of three digits in noise…."; Please explain the details; were they instructed to connect to the computer/iPad via a direct audio input or listen through a loudspeaker? This is a variable that can be different between the treatment and control groups and may affect the results. Please clarify. Also, please explain how bilateral recipients were tested, both at the baseline and exit sessions and at home for remote care group; monaural or binaural? 14.
Page 9, line 12: " Remote assistance Fitting" Please provide more detail; Explain to what capacity the participants were able to adjusted their devices with the remote assistance ( e.g. Volume and sensitivity or more advanced adjustments like…..). 15. Page 9, line 26: "It was not possible to receive logs of the changes made, so this was measured by self-report"; Please provide the details of the self-report process. Were the participants asked to jot down any changes they made or verbally report it? Did they provide feedback as the changes were made or at the end of the trial? 16.
Page 9, line 30: Has the development of the "Online support tool" been published? Please reference if it has been publish. 17.
Page9, lines 46-49: Please explain whether the participants received any training on the online support tool. Also, were they asked to use the tool as a mandatory part of the protocol? 18.
Page 9, line 56: How the upgraded processors were mapped? Were they mapped at the clinic and sent to the participants? 19.
Page 10, line 6: "Staff change management assessment "; this part should be explained in the participant section. They are participants in this study as per explained in the protocol by the authors. 20.
Page 10, line 16: "A formal staff change ………a smaller number of interviews were carried out to capture qualitative staff feedback." Why did you proceed and who was involved (Role in the clinic)? 21.
Page 10, line 46: Please explain the reason for choosing two speech in noise tests. i.e. BKB adaptive in noise and TDT. 22.
Page 11, line 31: "Participants in the remote care group attended a focus group at study exit". Why? And how this was measured? (e.g. via asking structured questions,…). 23.
Page 12, line 26: " No more deterioration in hearing" . No more is a very confusing term here. Does the author mean no significant change in hearing between the two groups? It is also suggested to change 'hearing' to speech understanding as per comment no.7) 24.
Page 12, line 29: Same as above regarding "no more". 25.
Page 12, lines 33-34: "Service users……...from feedback in online support tool"; It was not explained in the online support tool section that participants were asked to provide qualitative feedback. Please provide relevant information. 26.
Page 12, line 41: " Public and patient involvement". The purpose of this section is not clear. Is this part of the study design? Then it should be moved and sit under study design. How did these people contribute to the design of the study? 27.
Page 13, line 40: "Patients allocated to group" please change to " Patients allocated to groups". 28.
Page Page 21, Line 6: Could the improvement also be as a result of Direct Connection of the device to the computer/ipad?
VERSION 1 -AUTHOR RESPONSE
BMJ Open -Decision on Manuscript ID bmjopen-2017-019640 Editor Comments to Author: -The Discussion section should discuss the limitations of the study. Done -Please include a data sharing statement at the end of your paper. My apologies, I wasn't up to date with the requirement to include this. It is now included at the end of the manuscript.
Reviewer(s)' Comments to Author:
Reviewer: 1 Reviewer Name: Ariane Laplante-Lévesque This is a review of the manuscript titled "Feasibility of personalised remote long-term follow-up of people with cochlear implants: a Randomised Controlled Trial". This is an interesting manuscript presenting the results of a clinical trial of remote follow-up for UK adult users of cochlear implants. Remote care is acceptable, leads to patient activation, and to better hearing as measured by the triple digit test and the SSQ questionnaire. Here are some comments to improve an already very good manuscript.
-
The difference between the questions and hypotheses this feasibility RCT answers vs the questions and hypotheses a RCT would answer could be more clearly expressed and differentiated. Describe what the feasibility RCT was powered to find out and contrast with what an RCT would find out. The first paragraph of the Discussion now concludes that a RCT is possible. The feasibility outcomes differentiated this from a full RCT. We can't change any of the hypotheses and questions from those stated in the published Protocol.
This might be semantics, but when the authors write "clinical need" in the Abstract and Introduction, I understand it as "needs that the patient expresses/experiences". Some readers might understand it as "needs that the clinic/standard clinical pathway dictates". The authors might want to describe/clarify to avoid misunderstandings. Good point thanks. Have changed to 'when intervention is required' -This might also be semantics, but the secondary hypothesis #1 is that the hearing of the participants in the remote care group will not deteriorate more than the hearing of the participants in the control group participants ("no harm hypothesis"). The results show that the hearing of the control group participants deteriorated more than the hearing of the remote care group participants on the triple digit test and on the SSQ questionnaire. The authors report that these results lead to the rejection of the hypothesis. To me, these results confirm the hypothesis -indeed, the remote care did not harm. Ooh yes, you're right thanks. Have changed to secondary hypothesis 1 retained! -
The authors do a very good job at comparing two pathways: remote care and standard care. In the Discussion, when raising clinical implications, it could be interesting to nuance this duality between the two pathways and suggest that many patients will benefit from hybrid pathways (mix of remote and standard care), personalised according to their needs, preferences, etc. The authors hint to this in the Results section under Clinician preference for and experience of remote care and in the Conclusions, but the point could be made stronger. Thanks. I have added 'However a remote care pathway would not be desired or appropriate for all adults using implants, and flexibility in terms of personalised pathways is required. ' -I enjoyed the Discussion regarding the limitations of the PAM questionnaire for this population. What alternative measures do the authors suggest? What do the authors think of the related Partners in Health scale (Smith et al, 2017) ? Have commented in discussion thanks -Minor thing: Why was it important to randomise participants according to gender? There are few studies pointing to a gender effect in hearing care.
Clarified in manuscript 'Gender was included because men are more likely to use the internet than women, especially in the older age group' -Minor thing: It is really neat that the authors make their dataset openly available. However, the DOI provided did not work for me. The DOI will be registered at (fingers crossed) paper acceptance.
Reviewer: 2 Reviewer Name: Azadeh Ebrahimi-Madiseh Institution and Country: Ear Science Institute Australia (ESIA) / University of Western Australia (UWA), Australia Please state any competing interests or state 'None declared': There are no conflict of interests.
Please leave your comments for the authors below This manuscript is a randomised controlled trial to evaluate the feasibility of a personalised remote care for long term follow-ups of adult cochlear implant recipients. The study is unique in remotely evaluating all aspects of a CI recipient's progress including monitoring the function via speech perception tests, fine-tuning and rehabilitation.
Methodology is appropriate to answer the research question, however there are ambiguities in the manuscript that need to be addressed. Restructuring of the methodology section is highly recommended, as the contents do not flow. A suggestion would be to start with Trial design and setting, followed by randomisation and blinding, participants and recruitment, Intervention, Outcome measure, hypothesis, statistical analysis and data handling. There are minor explanations and clarifications required in the result and discussion section. Thanks so much for trying to improve the flow. I have changed it now to align with your suggestions, the Protocol paper, but also importantly the Page 3, line 18: "To assess the feasibility of comparing a remote care pathway to the standard pathway". Is the feasibility of the pathway assessed or the comparison? It is suggested that this part is changed to " To assess the feasibility of remote care pathway compared to the standard pathway". As this is a feasibility trial, I think it should stand as it is. This also agrees with the Protocol. 2.
Page 3, line 46: "Home hearing test", please reword to " hearing performance test " or " speech understanding (recognition) test" as the hearing of participants is not tested here rather their speech understanding. Actually I would argue that this is functioning more like a hearing test. It uses only nine digits, so does not require competency in speech understanding. I have changed to 'home hearing in noise test' 3.
Page 3, line 58: "One participant in the remote care group dropped out." This sentence does not sit comfortably in and is not related to the main outcome measures section. It is suggested that it is moved to the results section.
